![]() ![]() GYFFKZTYYAFCTR-AVXJPILUSA-N 4-Caffeoylquinic acid Natural products GYFFKZTYYAFCTR-AVXJPILUSA-N 0.000 claims abstract description 84.CWVRJTMFETXNAD-NXLLHMKUSA-N Neochlorogenic acid Chemical compound CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 claims abstract description 286.230000029964 regulation of glucose metabolic process Effects 0.000 title 2.230000037396 body weight Effects 0.000 title abstract description 24.239000000284 extract Substances 0.000 title abstract description 404.Assignors: DIKANSKY, JACQUES, IBARRA, ALVIN, ROLLER, MARC Publication of US20150072042A2 publication Critical patent/US20150072042A2/en Publication of US20160015766A2 publication Critical patent/US20160015766A2/en Priority to US15/173,765 priority patent/US10092613B2/en Application granted granted Critical Publication of US9358264B2 publication Critical patent/US9358264B2/en Status Active legal-status Critical Current Adjusted expiration legal-status Critical Links ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US12/263,292 external-priority patent/US20100112098A1/en Application filed by Naturex SA filed Critical Naturex SA Priority to US13/072,648 priority Critical patent/US9358264B2/en Publication of US20110223281A1 publication Critical patent/US20110223281A1/en Assigned to Naturex, S.A. Original Assignee Naturex SA Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Alvin Ibarra Marc Roller Jacques Dikansky Current Assignee (The listed assignees may be inaccurate. ![]() Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active, expires Application number US13/072,648 Other versions US20110223281A1 Google Patents Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolismÄownload PDF Info Publication number US9358264B2 US9358264B2 US13/072,648 US201113072648A US9358264B2 US 9358264 B2 US9358264 B2 US 9358264B2 US 201113072648 A US201113072648 A US 201113072648A US 9358264 B2 US9358264 B2 US 9358264B2 Authority US United States Prior art keywords green coffee coffee extract cqa svetol acid Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. ![]() Google Patents US9358264B2 - Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism In patients taking theophylline, adverse effects might be noticed when a rutaecarpine-containing herbal preparation is used concomitantly.US9358264B2 - Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism These results demonstrated that rutaecarpine treatment elevated CYP1A2 catalytic activity and theophylline excretion in rats. Pre-treatment of rats with 50 mg kg(-1) rutaecarpine caused a 3-fold increase in theophylline clearance and a 70%, 68% and 68% decrease in the area under the concentration-time curve (AUC), mean residence time (MRT) and half-life, respectively. Rutaecarpine pre-treatment increased the clearance of theophylline in a dose-dependent manner. Pharmacokinetic parameters of theophylline were determined using a microdialysis sampling method. In the lungs, EROD activity was elevated from an undetectable to a detectable level by rutaecarpine. In the kidney, rutaecarpine treatment caused a 3-fold increase in EROD activity. Oral treatment of Sprague-Dawley rats with 50 mg kg(-1) rutaecarpine for three days through a gastrogavage caused a 4- and 3-fold increase in liver microsomal 7-ethoxyresorufin O-deethylation (EROD) and 7-methoxyresorufin O-demethylation activity, respectively. To evaluate the pharmacokinetic interaction of theophylline with rutaecarpine, the effects of rutaecarpine on CYP1A2 activity and theophylline pharmacokinetics were investigated. The cytochrome P450 (CYP) 1A2 substrate, theophylline, is an important therapeutic agent for the treatment of asthma, but has a narrow therapeutic index. Rutaecarpine is a main active alkaloid present in the medicinal herb, Evodia rutaecarpa. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |